drugset / Trial / NCT07451665

Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

NCT07451665

Phase 4 Not yet recruiting 180 enrolled Chinese SLE Treatment And Research Group
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.

Timeline

Start
2026-04-01
Primary completion
2029-03-31
Completion
2029-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisone Other / unclassified
Subject SHR0302 Unknown 8 mg Oral
Subject Vanakizumab Unknown 240 mg Subcutaneous

Indications